Cite

    Youn, S. et al. (2021). An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel. Clinical nutrition. 40 (8), pp. 4888-4892. [Online].